Lupin's Q1 FY 2025-26 Quarter Results

Result Summary

• Lupin Ltd reported a 27.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 12.0%.
• Its expenses for the quarter were up by 9.8% QoQ and 5.5% YoY.
• The net profit increased 231.7% QoQ and increased 51.6% YoY.
• The earnings per share (EPS) of Lupin Ltd stood at 26.6 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Lupin Ltd is a major player in the pharmaceutical industry, primarily engaged in the development, manufacture, and sale of a wide range of generic and branded formulations and active pharmaceutical ingredients (APIs) globally. The company operates in multiple therapeutic areas including cardiovascular, diabetology, asthma, pediatrics, Central Nervous System (CNS), gastro-intestinal, anti-infectives, and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Recently, Lupin Ltd has focused on expanding its product portfolio and increasing its market presence through strategic partnerships and acquisitions. However, specific details on recent major developments were not available in the provided data.

Revenue

The financial performance of Lupin Ltd for Q1FY26 showcases a significant increase in total income, which reached ₹6347.38 crores. This marks a 27.2% rise from the previous quarter (Q4FY25) where the total income was ₹4990.04 crores and a 12.0% increase year-over-year compared to ₹5668.11 crores in Q1FY25. The substantial QoQ growth suggests an upward trajectory in revenue generation. These figures reflect a positive trend in the company's ability to enhance its income over the specified periods.

Profitability

Lupin Ltd's profitability metrics indicate robust growth. The Profit Before Tax (PBT) for Q1FY26 stands at ₹1415.54 crores, which is a significant increase of 184.4% from ₹497.71 crores in Q4FY25 and a 42.5% rise from ₹993.03 crores in Q1FY25. The Profit After Tax (PAT) also saw substantial growth, reaching ₹1221.46 crores, a 231.7% increase from the previous quarter's ₹368.22 crores and a 51.6% increase YoY from ₹805.54 crores. The Earnings Per Share (EPS) for Q1FY26 is ₹26.60, up 236.7% QoQ from ₹7.90 and 52.0% YoY from ₹17.50. These figures highlight the company's improved profitability over the periods compared.

Operating Metrics

Examining the operating metrics, the total expenses for Q1FY26 were reported at ₹4931.84 crores, reflecting an increase of 9.8% from Q4FY25's ₹4492.33 crores and a 5.5% increase YoY from ₹4675.08 crores. The tax paid this quarter amounted to ₹194.08 crores, showing a 49.9% increase from ₹129.49 crores in Q4FY25 and a marginal 3.5% increase from ₹187.49 crores in Q1FY25. These figures illustrate the cost dynamics and tax obligations that Lupin Ltd has managed during the quarter. The data provides insights into the company's operational efficiency and cost management strategies within the periods assessed.